A new study suggests that semaglutide, the active ingredient in Ozempic, may help decrease liver fat, inflammation, and ...

Weekly 2.4 mg semaglutide was linked to improved liver histology results but did not significantly reduce body pain compared ...

While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...

For patients with metabolic dysfunction-associated steatohepatitis and fibrosis, semaglutide is associated with improved liver histologic outcomes.

Oral semaglutide demonstrated superior cardiometabolic outcomes relative to placebo and active comparators, including empaglifozin, in T2D.

Orforglipron delivered efficacy that is comparable to injectable GLP-1s like Novo Nordisk’s semaglutide (Wegovy/Ozempic) and better than Novo Nordisk’s oral peptide version of semaglutide.

Compounded versions of Novo Nordisk’s Wegovy and Ozempic will ... When the FDA declared the shortage resolved for semaglutide, the main pharmaceutical ingredient in Wegovy and Ozempic, the ...

A federal judge April 24 rejected a bid by compounding pharmacies to continue selling less expensive copies of semaglutide, Novo Nordisk's blockbuster drug sold under the brands Wegovy and Ozempic.

The FDA may begin enforcement actions against pharmacies compounding unauthorized semaglutide after May 22, 2025. Novo Nordisk has filed 111 lawsuits in 32 states to stop the sale of dangerous ...

Compounders and telehealth providers have continued their offerings for both Novo's semaglutide and Eli Lilly's (LLY) tirzepatide — the key ingredient in diabetes drug Mounjaro and weight-loss ...

"We are pleased the court has rejected the compounders' attempts to undermine FDA's data-based decision that the shortage" of semaglutide is resolved, said Steve Benz, Novo Nordisk's corporate ...